Targeted Oncology2d
Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer
Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.
Medical Marketing & Media3d
A miniature horse farmer stars in Ferring’s bladder cancer ad campaign
The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.
Renal & Urology News3d
Bladder Cancer Outcomes After RARC Worse With Trigone-Urethra Tumors
The presence of residual tumor cells in the trigone and urethra after robot-assisted radical cystectomy (RARC) is associated with a higher tumor stage, positive margins, and cancer recurrence compared ...
Renal & Urology News5d
Cretostimogene Continues to Show Durable Response in BCG Unresponsive NMIBC
Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...